Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Bianca Bergamini; Julien Seneschal; Kristin J. Meyers; Frederick Durand; Ewa Haladyj; Gerard Espinosa; Jacob P. Thyssen

doi:10.1093/bjd/ljad279

Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Bianca Bergamini, Julien Seneschal, Kristin J. Meyers, Frederick Durand, Ewa Haladyj, Gerard Espinosa, Jacob P. Thyssen^*

^*Corresponding author af dette arbejde

Dermatologisk og Venerologisk Afdeling og Videncenter for Sårheling BFH

4 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	British Journal of Dermatology
Vol/bind	189
Udgave nummer	6
Sider (fra-til)	767-769
Antal sider	3
ISSN	0007-0963
DOI	https://doi.org/10.1093/bjd/ljad279
Status	Udgivet - dec. 2023

Adgang til dokumentet

10.1093/bjd/ljad279

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{3a23141c1ba34eb0b84388f691196ee8,

title = "Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance",

author = "Bianca Bergamini and Julien Seneschal and Meyers, \{Kristin J.\} and Frederick Durand and Ewa Haladyj and Gerard Espinosa and Thyssen, \{Jacob P.\}",

note = "Funding Information: This study was sponsored by Eli Lilly and Company. Funding Information: The authors wish to thank the study participants, investigators, trial staff, and healthcare practitioners for their contributions to the Eli Lilly global safety database. Writing support was provided by Fionnuala Murphy PhD and Dominika Kennedy PhD; medical review was provided by Katrin Holzwarth MD; and statistical review was provided by Xiaoyu Lu PhD, all employees of Eli Lilly and Company. Editorial support was provided by Mikaella Bernabe and Anthony Marca of Certara Synchrogenix. This study was sponsored by Eli Lilly and Company.",

year = "2023",

month = dec,

doi = "10.1093/bjd/ljad279",

language = "English",

volume = "189",

pages = "767--769",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

AU - Bergamini, Bianca

AU - Seneschal, Julien

AU - Meyers, Kristin J.

AU - Durand, Frederick

AU - Haladyj, Ewa

AU - Espinosa, Gerard

AU - Thyssen, Jacob P.

N1 - Funding Information: This study was sponsored by Eli Lilly and Company. Funding Information: The authors wish to thank the study participants, investigators, trial staff, and healthcare practitioners for their contributions to the Eli Lilly global safety database. Writing support was provided by Fionnuala Murphy PhD and Dominika Kennedy PhD; medical review was provided by Katrin Holzwarth MD; and statistical review was provided by Xiaoyu Lu PhD, all employees of Eli Lilly and Company. Editorial support was provided by Mikaella Bernabe and Anthony Marca of Certara Synchrogenix. This study was sponsored by Eli Lilly and Company.

PY - 2023/12

Y1 - 2023/12

UR - https://www.scopus.com/pages/publications/85177102524

U2 - 10.1093/bjd/ljad279

DO - 10.1093/bjd/ljad279

M3 - Letter

C2 - 37595142

AN - SCOPUS:85177102524

SN - 0007-0963

VL - 189

SP - 767

EP - 769

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -